HematologyNews.net

Hematology Xagena

Xagena Mappa
Medical Meeting
Cardiobase
Mediexplorer.it

Age-related clonal hematopoiesis is a common condition that is associated with increases in the risk of hematologic cancer and in all-cause mortality


The incidence of hematologic cancers increases with age. These cancers are associated with recurrent somatic mutations in specific genes.
Researchers hypothesized that such mutations would be detectable in the blood of some persons who are not known to have hematologic disorders.

They analyzed whole-exome sequencing data from DNA in the peripheral-blood cells of 17,182 persons who were unselected for hematologic phenotypes.
Researchers looked for somatic mutations by identifying previously characterized single-nucleotide variants and small insertions or deletions in 160 genes that are recurrently mutated in hematologic cancers.
The presence of mutations was analyzed for an association with hematologic phenotypes, survival, and cardiovascular events.

Detectable somatic mutations were rare in persons younger than 40 years of age but rose appreciably in frequency with age. Among persons 70 to 79 years of age, 80 to 89 years of age, and 90 to 108 years of age, these clonal mutations were observed in 9.5% ( 219 of 2300 persons ), 11.7% ( 37 of 317 ), and 18.4% ( 19 of 103 ), respectively.

The majority of the variants occurred in three genes: DNMT3A, TET2, and ASXL1.

The presence of a somatic mutation was associated with an increase in the risk of hematologic cancer ( hazard ratio, HR=11.1; 95% confidence interval [CI], 3.9 to 32.6 ), an increase in all-cause mortality ( HR=1.4; 95% CI, 1.1 to 1.8 ), and increases in the risks of incident coronary heart disease ( HR=2.0; 95% CI, 1.2 to 3.4 ) and ischemic stroke ( HR=2.6; 95% CI, 1.4 to 4.8 ).

In conclusion, age-related clonal hematopoiesis is a common condition that is associated with increases in the risk of hematologic cancer and in all-cause mortality, with the latter possibly due to an increased risk of cardiovascular disease. ( Xagena )

Jaiswal S et al, N Engl J Med 2014; 371:2488-2498

XagenaMedicine_2014



Indietro